KCL Capital’s Precision BioSciences DTIL Stock Holding History

KCL Capital’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-33	Closed	-$18K	–	46
2019 Q1	$18K	Buy	+33	New	+$17.5K	0.01%	35

Other funds holding DTIL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

KCL Capital's DTIL Position: Q2 2019 in Review

KCL Capital sold out of Precision BioSciences (DTIL) in Q2 2019, closing a stake of 33 shares — an estimated $18K sold.

KCL Capital first reported a position in DTIL in Q1 2019 and held it in 1 quarter. The position peaked at $18K in Q1 2019. 63 funds tracked by Wall St. Rank hold DTIL as of Q2 2019.

KCL Capital reported no remaining Precision BioSciences position as of Q2 2019 after selling out during the quarter.
KCL Capital sold 33 Precision BioSciences shares in Q2 2019, an estimated $18K.
KCL Capital first reported a position in Precision BioSciences in Q1 2019 and held it in 1 quarter.
KCL Capital's Precision BioSciences position peaked at $18K in Q1 2019.
63 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2019.

Based on KCL Capital's 13F filing for Q2 2019, filed 14 Aug 2019.